Navigation Links
Spero Therapeutics Hires Former Biomedical Advanced Research and Development Authority (BARDA) Anti-Infectives Program Chief
Date:1/19/2016

CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire-USNewswire/ -- Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced the appointment of Melissa Stundick, Ph.D., to the newly created leadership position of Head of Strategic Alliances.

In her new post, Dr. Stundick will navigate partnerships between Spero Therapeutics and other pharmaceutical, biopharmaceutical and government entities, and set objectives for collaborations. In addition, she will identify new opportunities as part of Spero's ongoing efforts to create novel treatments to combat antibiotic resistance.

"The considerable expertise Dr. Stundick brings to our team represents a significant step toward becoming a global, clinical stage company," said Ankit Mahadevia, M.D., Co-founder and Chief Executive Officer of Spero. "Melissa combines her deep understanding of the problem of antibiotic resistance with a broad knowledge of companies and organizations involved in complementary efforts that may serve as strategic partners for us in the future."

In her previous role as Chief of the Anti-Infectives Program at the United States Department of Health and Human Services (HHS), Dr. Stundick was responsible for forming public-private partnerships with pharmaceutical and biotech companies engaged in the development of anti-bacterials, antivirals and anti-toxins. Prior to HHS, Dr. Stundick was a lead analyst at Booz Allen where she provided scientific consultation to The Department of State, The National Center for Medical Intelligence and other organizations. Dr. Stundick received a PhD in Biochemistry, Cellular and Molecular Biology from The Johns Hopkins University School of Medicine. She also holds a Bachelor of Science in Chemistry from Bates College.

"At BARDA, I saw many different approaches to solving the growing issue of antibiotic resistance and look forward to using this knowledge to help Spero advance its pipeline of innovative products," said Melissa Stundick, Ph.D., Head of Strategic Alliances at Spero. "I'm honored to join a high-powered team with a novel approach to tackling these problems."

About Spero
Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections and is located in Cambridge, Massachusetts. The company's pipeline of anti-infective agents is one of the most unique in the industry-focused exclusively on Gram-negative bacterial infections. Spero is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative organisms. Spero's DHFR program is exploring the expansion of a novel antifolate's antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens. And, Spero's MvfR program is exploring the hypothesis of blunting the virulence of bugs, infections, essentially "buying time" so antibiotics can take effect. The investors in Spero include Atlas Ventures, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group, and The Partners Innovation Fund. For more information, please visit www.sperotherapeutics.com

 


'/>"/>
SOURCE Spero Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma to Enhance Anti-Infective Pipeline
2. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
3. Novelos Therapeutics Provides Product Pipeline Update
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
8. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
9. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
10. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
11. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2019)... ... August 19, 2019 , ... ... centers, today announced the findings of research validating the clinical impact of MedAware’s ... were published 7 August 2019 in the Journal of American Medical Informatics ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... to promote standards of excellence within the field of treatment for eating disorders, ... and communication with others who have a similar mission. , Founded in ...
(Date:8/16/2019)... ... August 16, 2019 , ... A new medical ... an alternative that both corrects the curve and maintains flexibility in the spine. ... techniques developed by medical staff of Shriners Hospitals for Children® — Philadelphia. It ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... August 16, 2019 , ... ... pharmaceutical and non-pharmaceutical cannabidiol (CBD) products across the CBD market in the United ... its crowdfunding campaign to raise $50 million on September 9, 2019. , Established ...
(Date:8/16/2019)... ... 16, 2019 , ... Dr. Demetri Arnaoutakis, a board-certified hair ... Network. , The Haute Beauty Network, well known for its exclusive and luxurious ... restoration expert and our newest addition to the Haute Beauty members-only network. , ...
(Date:8/15/2019)... ... 2019 , ... Jon O'Brien, president of Catholics for Choice, ... provide written assurance that they will comply with the Trump Administration’s domestic gag ... the new policy restricts providers and clinics that receive federal Title X funds. ...
(Date:8/14/2019)... ... August 14, 2019 , ... ScribeAmerica, the nation’s most ... a place on the Inc. magazine 500/5000 list today for the ninth consecutive ... of ScribeAmerica’s recognition as one of the fastest growing companies in America. ...
(Date:8/14/2019)... HENDERSON, Nev. (PRWEB) , ... August 13, 2019 , ... ... enlightenment and the purpose of doubt in your belief systems. , “Doubt can obliterate ... and start on the path to examining them to expand your understanding and your ...
Breaking Medicine News(10 mins):